BidaskClub upgraded shares of Aduro BioTech (NASDAQ:ADRO) from a hold rating to a buy rating in a report issued on Saturday.
ADRO has been the topic of several other research reports. Zacks Investment Research upgraded shares of Aduro BioTech from a hold rating to a buy rating and set a $7.50 price target on the stock in a report on Tuesday, March 6th. Bank of America cut their price target on shares of Aduro BioTech from $9.00 to $8.00 and set an underperform rating on the stock in a report on Friday, March 2nd. HC Wainwright set a $10.00 price target on shares of Aduro BioTech and gave the company a buy rating in a report on Friday, March 2nd. ValuEngine lowered shares of Aduro BioTech from a sell rating to a strong sell rating in a report on Friday, April 6th. Finally, Canaccord Genuity reiterated a buy rating on shares of Aduro BioTech in a research note on Friday, March 2nd. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company’s stock. Aduro BioTech has a consensus rating of Buy and a consensus target price of $13.92.
NASDAQ ADRO opened at $8.40 on Friday. Aduro BioTech has a one year low of $8.15 and a one year high of $8.70. The company has a market capitalization of $657.40 million, a P/E ratio of -5.92 and a beta of 2.10.
Aduro BioTech (NASDAQ:ADRO) last posted its quarterly earnings results on Wednesday, May 2nd. The biotechnology company reported ($0.28) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.07. Aduro BioTech had a negative net margin of 455.58% and a negative return on equity of 39.00%. The firm had revenue of $6.63 million for the quarter, compared to analyst estimates of $3.88 million. equities analysts expect that Aduro BioTech will post -1.27 EPS for the current fiscal year.
In other news, insider Stephen T. Isaacs sold 72,051 shares of Aduro BioTech stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $8.48, for a total transaction of $610,992.48. Following the sale, the insider now owns 231,380 shares in the company, valued at $1,962,102.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Stephen T. Isaacs sold 40,000 shares of Aduro BioTech stock in a transaction that occurred on Monday, April 2nd. The shares were sold at an average price of $8.91, for a total transaction of $356,400.00. Following the sale, the insider now owns 245,746 shares in the company, valued at approximately $2,189,596.86. The disclosure for this sale can be found here. Insiders have sold 158,925 shares of company stock worth $1,332,336 in the last quarter. Insiders own 5.00% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. MetLife Investment Advisors LLC purchased a new stake in shares of Aduro BioTech during the fourth quarter valued at approximately $140,000. Fox Run Management L.L.C. raised its stake in shares of Aduro BioTech by 91.4% during the fourth quarter. Fox Run Management L.L.C. now owns 22,775 shares of the biotechnology company’s stock valued at $171,000 after purchasing an additional 10,875 shares during the period. Nisa Investment Advisors LLC raised its stake in shares of Aduro BioTech by 2,294.1% during the fourth quarter. Nisa Investment Advisors LLC now owns 24,420 shares of the biotechnology company’s stock valued at $183,000 after purchasing an additional 23,400 shares during the period. Wilbanks Smith & Thomas Asset Management LLC acquired a new stake in shares of Aduro BioTech during the fourth quarter worth approximately $191,000. Finally, Quantitative Systematic Strategies LLC acquired a new stake in shares of Aduro BioTech during the first quarter worth approximately $238,000. Institutional investors own 47.26% of the company’s stock.
About Aduro BioTech
Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.